IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
11 avr. 2023 08h00 HE
|
IN8bio, Inc
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observedNew...
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 16h15 HE
|
IN8bio, Inc
All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated...
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
16 mars 2023 08h00 HE
|
IN8bio, Inc
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this...
IN8bio to Present at the Cowen 43rd Annual Healthcare Conference
01 mars 2023 08h00 HE
|
IN8bio, Inc
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
23 févr. 2023 07h00 HE
|
IN8bio, Inc
Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling...
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
21 févr. 2023 07h00 HE
|
IN8bio, Inc
NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference
17 janv. 2023 07h00 HE
|
IN8bio, Inc
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
05 janv. 2023 07h00 HE
|
IN8bio, Inc
All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial...
IN8bio to Present at Biotech Showcase 2023 in San Francisco
03 janv. 2023 07h00 HE
|
IN8bio, Inc
Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage...
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
12 déc. 2022 07h00 HE
|
IN8bio, Inc
Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months)INB-100 continues...